WuXi PharmaTech welcomes Felix Hsu as SVP of U.S. operations

SHANGHAI WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced Felix Hsu has been appointed to SVP of the company's U.S. operations.

Prior to joining WuXi, Hsu spent 14 years with Medtronic where he had broad experience as a product manager and business leader. Hsu also served in product management, sales management and strategic planning roles at Abbott Laboratories and as a business manager at Sabratek.

In his new role, Hsu will be responsible for WuXi’s U.S. business. A significant portion of U.S. revenues are derived from serving the medical device industry, where Hsu has extensive experience.

“I am very pleased to welcome Felix on board as we continue to strengthen our U.S. management team,” commented Ge Li, chairman and CEO of WuXi. “Our U.S. operations offer a range of testing services critical to the successful development and regulatory approval of new biologics and medical devices. We expect our U.S. business will grow under Felix's leadership.”